• Earlier in 2026, Praxis Precision Medicines reported that the FDA accepted New Drug Applications for ulixacaltamide in essential tremor and relutrigine in developmental and epileptic encephalopathies, with target action dates in 2027 and key clinical readouts for other assets expected later in 2026.
• This twin NDA acceptance marks a major regulatory inflection for Praxis, elevating its late-stage CNS portfolio from purely clinical-stage potential to nearer-term commercialization prospects.
• We’ll now examine how the FDA’s acceptance of two lead NDAs reshapes Praxis’s existing investment narrative and risk-reward profile.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Praxis Precision Medicines Investment Narrative Recap

To own Praxis today, you need to believe that its focused CNS pipeline can convert clinical momentum into approved medicines and commercial traction, despite ongoing losses and dilution. The twin NDA acceptances for ulixacaltamide and relutrigine bring the approval conversation forward, but the most important near term catalyst still sits with late 2026 data from vormatrigine and additional relutrigine studies, while the biggest current risk remains that any of these key readouts underperform expectations.

Among recent developments, the FDA priority review of relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies stands out as most connected to the NDA news. It reinforces Praxis’s attempt to build a multi asset epilepsy franchise where upcoming vormatrigine and relutrigine data could either support a multi product portfolio or expose the concentration risk in a small set of late stage programs.

Yet while the approvals path is moving forward, investors should also be aware of the funding and dilution risk if multiple late stage trials do not break in Praxis’s favor...

Praxis Precision Medicines' narrative projects $724.1 million revenue and $89.5 million earnings by 2029. This requires 359.5% yearly revenue growth and an earnings increase of about $362.5 million from -$273.0 million today.

Uncover how Praxis Precision Medicines' forecasts yield a $449.13 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming revenue of about US$76.6 million and earnings near US$12.3 million by 2028, which is far more cautious than narratives that lean on multiple successful late stage epilepsy readouts and rapid uptake, so it is worth comparing those views as you think about how this year’s NDA acceptances might reshape expectations.

Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be worth over 8x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Praxis Precision Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Praxis Precision Medicines' overall financial health at a glance.

No Opportunity In Praxis Precision Medicines?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 46 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.